5.3.99.5 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15278626&form=6&db=m A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits. therapeutic application,unassigned 2,0 5.3.99.5 Acidosis, Respiratory http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19237908&form=6&db=m Differential responses of porcine anterior spinal and middle cerebral arteries to carbon dioxide and pH. ongoing research,therapeutic application,unassigned 1,2,0 5.3.99.5 Acute Coronary Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9890391&form=6&db=m A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers. causal interaction,therapeutic application,unassigned 2,2,0 5.3.99.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1715995&form=6&db=m The protective effects of Iloprost and thromboxane synthetase inhibitor, UK 38485, against glycerol--induced acute renal failure in rats. ongoing research,therapeutic application,unassigned 3,2,0 5.3.99.5 Acute Kidney Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1819724&form=6&db=m Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane. therapeutic application,unassigned 1,0 5.3.99.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1399989&form=6&db=m Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 5.3.99.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1433403&form=6&db=m Differential effects of cyclo-oxygenase and thromboxane synthetase inhibition on ventilation-perfusion relationships in acid aspiration-induced acute lung injury. ongoing research,unassigned 2,0 5.3.99.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3985125&form=6&db=m Mediators of lung injury in mice following systemic activation of complement. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11422304&form=6&db=m Ketoconazole and pulmonary failure after esophagectomy: a prospective clinical trial. causal interaction,ongoing research,therapeutic application,unassigned 4,1,3,0 5.3.99.5 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15851882&form=6&db=m Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury. unassigned - 5.3.99.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6393859&form=6&db=m The effect of prostaglandin modulators on prostate tumor growth and metastasis. therapeutic application,unassigned 4,0 5.3.99.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8630277&form=6&db=m Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630766&form=6&db=m The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ongoing research,unassigned 4,0 5.3.99.5 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Adenocarcinoma of Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24556579&form=6&db=m Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase. causal interaction,therapeutic application,unassigned 2,2,0 5.3.99.5 Albuminuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30542084&form=6&db=m Diverse associations between oxidative stress and thromboxane A2 in hypertensive glomerular injury. causal interaction,unassigned 1,0 5.3.99.5 Anaphylaxis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2879917&form=6&db=m N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8781596&form=6&db=m Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2947145&form=6&db=m [Treatment of angina pectoris. New perspectives] causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Angina Pectoris http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3941213&form=6&db=m Selective thromboxane A2 synthetase inhibition in vasospastic angina pectoris. diagnostic usage,therapeutic application,unassigned 3,2,0 5.3.99.5 Angina, Stable http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538553&form=6&db=m Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,1,0 5.3.99.5 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3953390&form=6&db=m Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. ongoing research,unassigned 2,0 5.3.99.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8376914&form=6&db=m The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. ongoing research,therapeutic application,unassigned 1,3,0 5.3.99.5 Arterial Occlusive Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27511998&form=6&db=m 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 5.3.99.5 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128168&form=6&db=m Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345. diagnostic usage,unassigned 3,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1889493&form=6&db=m The role of thromboxane in allergen-induced asthmatic responses. diagnostic usage,therapeutic application,unassigned 2,2,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1952565&form=6&db=m Effect of DP-1904, a new thromboxane A2 synthetase inhibitor, on guinea pig experimental asthma. therapeutic application,unassigned 4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2192187&form=6&db=m [Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects] ongoing research,therapeutic application,unassigned 3,1,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2203618&form=6&db=m Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. diagnostic usage,ongoing research,unassigned 2,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2447593&form=6&db=m Effect of OKY-046, a new thromboxane A2 synthetase inhibitor, on experimental asthma in guinea pigs. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7758058&form=6&db=m Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8950950&form=6&db=m [Thromboxane A2 synthetase inhibitor in asthma therapy] causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9182072&form=6&db=m Thromboxane A2 and related prostaglandins in airways. causal interaction,therapeutic application,unassigned 1,1,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9669829&form=6&db=m A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients. ongoing research,unassigned 3,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9792572&form=6&db=m Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. causal interaction,ongoing research,therapeutic application,unassigned 1,3,2,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11829716&form=6&db=m Therapeutic potential of thromboxane inhibitors in asthma. causal interaction,therapeutic application,unassigned 2,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14720071&form=6&db=m Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21449675&form=6&db=m Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. causal interaction,unassigned 3,0 5.3.99.5 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32119686&form=6&db=m Genome-wide interaction study reveals age-dependent determinants of responsiveness to inhaled corticosteroids in individuals with asthma. diagnostic usage,unassigned 3,0 5.3.99.5 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9596415&form=6&db=m Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2947145&form=6&db=m [Treatment of angina pectoris. New perspectives] causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3010578&form=6&db=m Contribution of arachidonic acid metabolites to atherosclerosis. therapeutic application,unassigned 4,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11331452&form=6&db=m The combined use of prostaglandin I2 analogue (OP-2507) and thromboxane A2 synthetase inhibitor (OKY-046) strongly inhibits atherosclerosis of aortic allografts in rats. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19735918&form=6&db=m Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition. causal interaction,unassigned 1,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20383787&form=6&db=m Thromboxane synthase expression and thromboxane A(2) production in the atherosclerotic lesion. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21397034&form=6&db=m BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. causal interaction,therapeutic application,unassigned 4,2,0 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27019366&form=6&db=m Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis. unassigned - 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29623931&form=6&db=m Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 5.3.99.5 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31026093&form=6&db=m Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population. diagnostic usage,ongoing research,unassigned 2,4,0 5.3.99.5 Blood Platelet Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3920834&form=6&db=m [Genetic defects of prostaglandin and thromboxane synthesis] causal interaction,unassigned 1,0 5.3.99.5 Bone Resorption http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7232765&form=6&db=m The effect of imidazole-analogues on bone resorption in vitro: a suggested role for thromboxane A2. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Bradycardia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3116626&form=6&db=m Direct and indirect effects of leukotriene D4 on the lungs of unanesthetized sheep. causal interaction,unassigned 2,0 5.3.99.5 Bradycardia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6807698&form=6&db=m Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement. therapeutic application,unassigned 2,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2077148&form=6&db=m Role of platelets as a factor aggravating cerebral ischemia. causal interaction,ongoing research,unassigned 1,2,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2513212&form=6&db=m Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats. ongoing research,therapeutic application,unassigned 4,1,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3544349&form=6&db=m Inhibition of thromboxane A2 production does not improve post-ischemic brain hypoperfusion in the dog. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3790357&form=6&db=m [Protective effect of thromboxane A2 synthetase inhibitor (trapidil) on acutely-induced cerebral ischemia] ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542131&form=6&db=m Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 5.3.99.5 Brain Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11384620&form=6&db=m Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 5.3.99.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2497973&form=6&db=m Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16250911&form=6&db=m Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 5.3.99.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19276290&form=6&db=m Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29872696&form=6&db=m Inhibiting breast cancer by targeting the thromboxane A2 pathway. diagnostic usage,unassigned 3,0 5.3.99.5 Bronchial Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8835638&form=6&db=m Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs. therapeutic application,unassigned 1,0 5.3.99.5 Bronchial Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8955866&form=6&db=m Effects of 1-[3-(4-benzhydryl-1-piperazinyl)propyl]-3- (1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid with thromboxane A2 synthetase inhibitory and H1-blocking activities on anaphylactic bronchospasm. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Bronchiectasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2203618&form=6&db=m Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. diagnostic usage,ongoing research,unassigned 2,4,0 5.3.99.5 Bronchitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2192187&form=6&db=m [Thromboxane A2 could be involved in bronchial hyperresponsiveness to methacholine in asthmatic subjects but not in bronchitic subjects] ongoing research,therapeutic application,unassigned 3,1,0 5.3.99.5 Bronchitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2203618&form=6&db=m Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. diagnostic usage,ongoing research,unassigned 2,4,0 5.3.99.5 Bronchitis, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8586126&form=6&db=m Effect of thromboxane A2 synthetase inhibitor, OKY-046, on sputum in chronic bronchitis and diffuse panbronchiolitis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Calcinosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8466554&form=6&db=m The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition. causal interaction,unassigned 1,0 5.3.99.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2497973&form=6&db=m Differential effects of tranylcypromine and imidazole on mammary carcinogenesis in rats fed low and high fat diets. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17880908&form=6&db=m Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 5.3.99.5 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26518146&form=6&db=m Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. causal interaction,unassigned 3,0 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3755610&form=6&db=m Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation. therapeutic application,unassigned 1,0 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7946454&form=6&db=m Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10623605&form=6&db=m Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14742249&form=6&db=m Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15067173&form=6&db=m Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17603559&form=6&db=m Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 5.3.99.5 Carcinoma, Lewis Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10623605&form=6&db=m Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 5.3.99.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870920&form=6&db=m Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21388528&form=6&db=m Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 5.3.99.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24480048&form=6&db=m Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24695790&form=6&db=m 18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 5.3.99.5 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26518146&form=6&db=m Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. causal interaction,unassigned 3,0 5.3.99.5 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7946454&form=6&db=m Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase. causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 5.3.99.5 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Carcinoma, Transitional Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Carcinoma, Transitional Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17603559&form=6&db=m Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 5.3.99.5 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419696&form=6&db=m A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 5.3.99.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2997839&form=6&db=m Thromboxane synthetase inhibitors, thromboxane receptor antagonists, and aspirin in cardiovascular disease. therapeutic application,unassigned 3,0 5.3.99.5 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8964509&form=6&db=m Genomic structure and polymorphism of the human thromboxane synthase-encoding gene. unassigned - 5.3.99.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542131&form=6&db=m Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 5.3.99.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8327988&form=6&db=m Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9513204&form=6&db=m [Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery] causal interaction,diagnostic usage,ongoing research,unassigned 1,2,4,0 5.3.99.5 Cerebral Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19403042&form=6&db=m Association of polymorphisms in thromboxane A2 receptor and thromboxane A synthase 1 with cerebral infarction in a Korean population. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,2,2,4 5.3.99.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3741043&form=6&db=m [Treatment of occlusive cerebrovascular disease with a selective thromboxane A2 synthetase inhibitor] causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3883580&form=6&db=m The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. causal interaction,therapeutic application,unassigned 3,3,0 5.3.99.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15764681&form=6&db=m Testosterone treatment increases thromboxane function in rat cerebral arteries. causal interaction,therapeutic application,unassigned 1,3,0 5.3.99.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19114962&form=6&db=m The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 5.3.99.5 Cerebrovascular Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31708774&form=6&db=m Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Cholestasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7544015&form=6&db=m The protective effect of thromboxane synthetase inhibitor UK 38485 against bile duct ligation induced liver injury. ongoing research,unassigned 3,0 5.3.99.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2946624&form=6&db=m Prostaglandin regulation of colonic blood flow in rabbit colitis. unassigned - 5.3.99.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20694740&form=6&db=m Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis. causal interaction,ongoing research,therapeutic application,unassigned 3,3,2,0 5.3.99.5 Colitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30063735&form=6&db=m Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis. diagnostic usage,ongoing research,unassigned 2,1,0 5.3.99.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7743303&form=6&db=m Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10210278&form=6&db=m Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. ongoing research,therapeutic application,unassigned 4,4,0 5.3.99.5 Colitis, Ulcerative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11986343&form=6&db=m Thromboxane synthase immunohistochemistry in inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 5.3.99.5 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16709411&form=6&db=m Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,4,0 5.3.99.5 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=66560&form=6&db=m Possible congenital defect in platelet thromboxane synthetase. diagnostic usage,ongoing research,unassigned 4,2,0 5.3.99.5 Congenital Abnormalities http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6089937&form=6&db=m Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. unassigned - 5.3.99.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1965841&form=6&db=m [Pathogenetic and therapeutic significance of the angioprotective systems in patients with coronary arteriosclerosis] causal interaction,unassigned 4,0 5.3.99.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3159226&form=6&db=m Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 5.3.99.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3323562&form=6&db=m Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. causal interaction,ongoing research,therapeutic application,unassigned 4,1,2,0 5.3.99.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538740&form=6&db=m Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 5.3.99.5 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22959706&form=6&db=m EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Coronary Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6402000&form=6&db=m Effects of dazoxiben on exercise performance in chronic stable angina. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2427826&form=6&db=m Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs. causal interaction,therapeutic application,unassigned 1,1,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2513429&form=6&db=m Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3344655&form=6&db=m Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion. causal interaction,therapeutic application,unassigned 1,3,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3953390&form=6&db=m Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. ongoing research,unassigned 2,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8426016&form=6&db=m Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. ongoing research,unassigned 3,0 5.3.99.5 Coronary Occlusion http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8459087&form=6&db=m Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. causal interaction,therapeutic application,unassigned 3,3,0 5.3.99.5 Coronary Stenosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1453545&form=6&db=m Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis. unassigned - 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1521557&form=6&db=m Effects of Y-20811, a thromboxane A2 synthetase inhibitor, on experimentally induced coronary thrombosis in anesthetized dogs. causal interaction,ongoing research,therapeutic application,unassigned 1,2,4,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145320&form=6&db=m Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. therapeutic application,unassigned 2,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2959103&form=6&db=m Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3183064&form=6&db=m Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542526&form=6&db=m Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8319746&form=6&db=m Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis. ongoing research,therapeutic application,unassigned 1,1,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9226103&form=6&db=m DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 5.3.99.5 Coronary Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12721335&form=6&db=m BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8778479&form=6&db=m [Chronic persistent coughing successfully treated with ozagrel] unassigned - 5.3.99.5 Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9126880&form=6&db=m Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Cough http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11796690&form=6&db=m Involvement of thromboxane A(2) in airway mucous cells in asthma-related cough. therapeutic application,unassigned 1,0 5.3.99.5 Crohn Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11552902&form=6&db=m Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Death, Sudden, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1696668&form=6&db=m Effects of combined thromboxane synthetase inhibition/thromboxane receptor antagonism in two models of sudden cardiac death in the canine: limited role for thromboxane. ongoing research,therapeutic application,unassigned 3,1,0 5.3.99.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33020931&form=6&db=m Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. ongoing research,therapeutic application,unassigned 1,4,0 5.3.99.5 Dementia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34534530&form=6&db=m Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia. ongoing research,unassigned 3,0 5.3.99.5 Dementia, Vascular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33346090&form=6&db=m Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. causal interaction,therapeutic application,unassigned 2,1,0 5.3.99.5 Dermatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17429442&form=6&db=m Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. causal interaction,unassigned 2,0 5.3.99.5 Diabetes Mellitus, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10680643&form=6&db=m Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. therapeutic application,unassigned 4,0 5.3.99.5 Diabetes Mellitus, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34534530&form=6&db=m Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia. ongoing research,unassigned 3,0 5.3.99.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2073870&form=6&db=m Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 5.3.99.5 Diabetes Mellitus, Type 2 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8573760&form=6&db=m Prostaglandins and diabetic nephropathy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,1,0 5.3.99.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1350991&form=6&db=m A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. therapeutic application,unassigned 4,0 5.3.99.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2073870&form=6&db=m Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 5.3.99.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2077412&form=6&db=m Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Diabetic Nephropathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8445289&form=6&db=m Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3519046&form=6&db=m Specific thromboxane synthetase inhibition and retinopathy in insulin-dependent diabetics. causal interaction,therapeutic application,unassigned 3,1,0 5.3.99.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9499164&form=6&db=m Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Diabetic Retinopathy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18952655&form=6&db=m Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. ongoing research,unassigned 2,0 5.3.99.5 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2080492&form=6&db=m Role of activated platelets in endotoxin-induced DIC in rats. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7893785&form=6&db=m The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome. ongoing research,unassigned 3,0 5.3.99.5 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21617900&form=6&db=m Up-regulation of thromboxane A(2) impairs cerebrovascular eNOS function in aging atherosclerotic mice. unassigned - 5.3.99.5 Embolic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12910992&form=6&db=m [The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction] causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Embolism, Air http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3457388&form=6&db=m Effect of thromboxane synthetase inhibitors (OKY-046, OKY-1580) on experimentally induced air embolism in anesthetized dogs. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Endometriosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27519725&form=6&db=m Anti-platelet therapy is efficacious in treating endometriosis induced in mouse. ongoing research,therapeutic application,unassigned 3,3,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1757360&form=6&db=m Thromboxane synthase inhibition and cardiopulmonary function during endotoxemia in sheep. therapeutic application,unassigned 1,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2286607&form=6&db=m The effect of thromboxane synthetase inhibition on cardiopulmonary function during endotoxemia in sheep. ongoing research,unassigned 2,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3080926&form=6&db=m Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. therapeutic application,unassigned 4,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3118413&form=6&db=m Dose-dependent effects of a pyridoquinazoline thromboxane synthetase inhibitor on arachidonic acid metabolites and hemodynamics during E. coli endotoxemia in anesthetized sheep. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3979000&form=6&db=m Dazoxiben in human sepsis and adult respiratory distress syndrome. causal interaction,unassigned 4,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9223660&form=6&db=m Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock. ongoing research,unassigned 3,0 5.3.99.5 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10774620&form=6&db=m Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. ongoing research,unassigned 3,0 5.3.99.5 Eosinophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8527955&form=6&db=m Effects of a thromboxane synthase inhibitor (CS-518) on the eosinophil-dependent late asthmatic response and airway hyperresponsiveness in guinea pigs. ongoing research,therapeutic application,unassigned 3,3,0 5.3.99.5 Epiretinal Membrane http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18952655&form=6&db=m Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. ongoing research,unassigned 2,0 5.3.99.5 Erectile Dysfunction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3389962&form=6&db=m Possible utility of a thromboxane synthetase inhibitor in preventing penile vascular changes and impotence during aging. ongoing research,unassigned 1,0 5.3.99.5 Erythema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128168&form=6&db=m Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345. diagnostic usage,unassigned 3,0 5.3.99.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3277911&form=6&db=m Role of thromboxane A2 in the hypotensive effect of captopril in essential hypertension. ongoing research,therapeutic application,unassigned 4,2,0 5.3.99.5 Essential Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8340155&form=6&db=m Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3545698&form=6&db=m Thromboxane synthetase inhibition in primary pulmonary hypertension. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,3 5.3.99.5 Familial Primary Pulmonary Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12040360&form=6&db=m Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. causal interaction,ongoing research,unassigned 3,3,0 5.3.99.5 Feline Infectious Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9637307&form=6&db=m Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9303217&form=6&db=m Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats. ongoing research,unassigned 3,0 5.3.99.5 Fetal Growth Retardation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26974824&form=6&db=m Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Fibrosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3557705&form=6&db=m Dissociation between thromboxane generation and metastatic potential in cells from a murine fibrosarcoma. Studies with a selective thromboxane synthase inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 5.3.99.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118886&form=6&db=m Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 5.3.99.5 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20165694&form=6&db=m Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9596415&form=6&db=m Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11550298&form=6&db=m Thromboxane synthase regulates the migratory phenotype of human glioma cells. causal interaction,ongoing research,unassigned 2,3,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11807649&form=6&db=m Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11844270&form=6&db=m Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14586398&form=6&db=m Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. causal interaction,therapeutic application,unassigned 4,2,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15118886&form=6&db=m Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,1,1 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18825315&form=6&db=m Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 5.3.99.5 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20165694&form=6&db=m Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1388004&form=6&db=m Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs. ongoing research,unassigned 3,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1588545&form=6&db=m Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1827969&form=6&db=m Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis. causal interaction,ongoing research,therapeutic application,unassigned 4,4,1,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2936143&form=6&db=m Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis. ongoing research,unassigned 4,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2976425&form=6&db=m Effects of a specific thromboxane synthetase inhibitor on development of experimental Dirofilaria immitis immune complex glomerulonephritis in the dog. ongoing research,therapeutic application,unassigned 3,2,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3490944&form=6&db=m Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat. causal interaction,ongoing research,unassigned 1,2,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3682335&form=6&db=m [Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,1,4 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6228742&form=6&db=m Effects of a selective thromboxane A2 synthetase inhibitor on immune complex glomerulonephritis. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10560941&form=6&db=m Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Glomerulonephritis, IGA http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9105763&form=6&db=m Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 5.3.99.5 Glomerulonephritis, Membranoproliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1588545&form=6&db=m Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Glomerulonephritis, Membranous http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8982653&form=6&db=m Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats. unassigned - 5.3.99.5 Gout http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26252103&form=6&db=m [Association of single nucleotide polymorphisms of cytochrome P450 gene with susceptibility to gout in ethnic Han males from coastal regions of Shandong province]. diagnostic usage,unassigned 3,0 5.3.99.5 Heart Arrest http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3755113&form=6&db=m [Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151] causal interaction,therapeutic application,unassigned 1,2,0 5.3.99.5 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6114260&form=6&db=m Thromboxane synthase inhibition in patients with atherosclerotic heart disease. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,2,0 5.3.99.5 Heart Failure http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1833887&form=6&db=m [Right heart function and endotoxemia in animals] causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Hepatitis A http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23684750&form=6&db=m Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23684750&form=6&db=m Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Hepatitis, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6593268&form=6&db=m Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 5.3.99.5 Hernias, Diaphragmatic, Congenital http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3841361&form=6&db=m Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile. causal interaction,unassigned 3,0 5.3.99.5 Hydronephrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2539462&form=6&db=m Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989. ongoing research,therapeutic application,unassigned 1,3,0 5.3.99.5 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3326847&form=6&db=m A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 5.3.99.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2437053&form=6&db=m Effect of thromboxane A2 synthetase inhibitor on immediate-type hypersensitivity reactions. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 5.3.99.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9669829&form=6&db=m A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients. ongoing research,unassigned 3,0 5.3.99.5 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21449675&form=6&db=m Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. causal interaction,unassigned 3,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1726988&form=6&db=m [Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,4,4 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1909312&form=6&db=m Cyclooxygenase pathway mediates lung injury induced by phorbol and platelets. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2139470&form=6&db=m Contrasting effect of thromboxane synthase inhibitors and a thromboxane receptor antagonist on the development of angiotensin II-salt-induced hypertension in rats. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2147173&form=6&db=m Thromboxane A2 and development of genetic hypertension in the Lyon rat strain. ongoing research,unassigned 2,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2405549&form=6&db=m Cyclosporine-induced hypertension in sheep. The role of thromboxanes. ongoing research,unassigned 4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2717519&form=6&db=m Pharmacokinetics of furegrelate after oral administration to normal humans. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3287320&form=6&db=m Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel. therapeutic application,unassigned 2,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3413813&form=6&db=m Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3922775&form=6&db=m Delay of the initiation of hypertension in spontaneously hypertensive rats by CV-4151, a specific thromboxane A2 synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6209508&form=6&db=m Thromboxane synthetase inhibitor UK38,485 lowers blood pressure in the adult spontaneously hypertensive rat. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6897296&form=6&db=m Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone. unassigned - 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9453302&form=6&db=m Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11641301&form=6&db=m Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15207526&form=6&db=m Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17612651&form=6&db=m Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18056786&form=6&db=m Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22493072&form=6&db=m Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22837860&form=6&db=m Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. causal interaction,unassigned 3,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23676973&form=6&db=m Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803333&form=6&db=m Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24418882&form=6&db=m Effects of continuous ingestion of hesperidin and glucosyl hesperidin on vascular gene expression in spontaneously hypertensive rats. diagnostic usage,unassigned 1,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26974824&form=6&db=m Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32888289&form=6&db=m Identification of Hub Genes Associated with Hypertension and Their Interaction with miRNA Based on Weighted Gene Coexpression Network Analysis (WGCNA) Analysis. unassigned - 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1432274&form=6&db=m Thromboxane synthetase inhibition produces maternal and fetal vasodilation during ovine pregnancy-induced hypertension: a Doppler flow velocimetric study. ongoing research,unassigned 2,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2589456&form=6&db=m Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3177514&form=6&db=m Thromboxane synthetase inhibition in pregnancy-induced hypertension. causal interaction,unassigned 3,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3189458&form=6&db=m Erythrocyte morphologic features and serum chemistry studies in ovine pregnancy-induced hypertension treated with thromboxane synthetase inhibitors. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3238644&form=6&db=m Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3605254&form=6&db=m Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension. causal interaction,ongoing research,unassigned 3,2,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6362418&form=6&db=m Preliminary observations on treatment of pregnancy-induced hypertension with a thromboxane synthetase inhibitor. therapeutic application,unassigned 4,0 5.3.99.5 Hypertension, Pregnancy-Induced http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8016393&form=6&db=m Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1559913&form=6&db=m Hyperbaric oxygen toxicity: role of thromboxane. causal interaction,therapeutic application,unassigned 2,4,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1594324&form=6&db=m Impact of prostaglandin and thromboxane synthesis blockade on disposition of group B streptococcus in lung and liver of intact piglet. causal interaction,therapeutic application,unassigned 3,3,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1711633&form=6&db=m In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase. ongoing research,therapeutic application,unassigned 4,2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2318970&form=6&db=m Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury. therapeutic application,unassigned 2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2506581&form=6&db=m Lipoxygenase and cyclooxygenase blockade by BW755C does not prevent the secondary phase of septic pulmonary hypertension. ongoing research,therapeutic application,unassigned 4,2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2673060&form=6&db=m Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3056674&form=6&db=m Selective inhibition of thromboxane synthetase reduces group-B-beta-hemolytic-streptococci-induced pulmonary hypertension in piglets. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3134642&form=6&db=m Thromboxane-associated pulmonary hypertension during three types of gram-positive bacteremia in piglets. causal interaction,unassigned 2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3409518&form=6&db=m Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3841361&form=6&db=m Extracorporeal membrane oxygenation and congenital diaphragmatic hernia: modification of the pulmonary vasoactive profile. causal interaction,unassigned 3,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3979000&form=6&db=m Dazoxiben in human sepsis and adult respiratory distress syndrome. causal interaction,unassigned 4,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6822668&form=6&db=m Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. causal interaction,therapeutic application,unassigned 2,2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6896528&form=6&db=m Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7759418&form=6&db=m Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs. causal interaction,therapeutic application,unassigned 3,2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8317791&form=6&db=m Capsular type-specific polysaccharide partially inhibits group B Streptococcus-induced pulmonary hypertension. unassigned - 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8356015&form=6&db=m Intrinsic microbicidal activity and pulmonary hypertension in isolated newborn piglet lungs. causal interaction,ongoing research,therapeutic application,unassigned 1,1,3,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10323263&form=6&db=m Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade. therapeutic application,unassigned 2,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15802364&form=6&db=m Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,3,1 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20693398&form=6&db=m Protein complex formation with heat shock protein 90 in chronic hypoxia-induced pulmonary hypertension in newborn piglets. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419696&form=6&db=m A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 5.3.99.5 Hypoparathyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3801615&form=6&db=m [Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism] ongoing research,unassigned 3,0 5.3.99.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1568300&form=6&db=m Putative mechanism of hypotensive action of platelet-activating factor in dogs. causal interaction,unassigned 1,0 5.3.99.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2578591&form=6&db=m Amelioration of the deleterious effects of platelets activated during cardiopulmonary bypass. Comparison of a thromboxane synthetase inhibitor and a prostacyclin analogue. therapeutic application,unassigned 2,0 5.3.99.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2910814&form=6&db=m Thromboxane synthase inhibition enhances action of converting enzyme inhibitors. therapeutic application,unassigned 2,0 5.3.99.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6807698&form=6&db=m Reversal of bradykinin-induced reflex tachycardia to bradycardia by captopril; evidence for prostacyclin involvement. therapeutic application,unassigned 2,0 5.3.99.5 Hypotension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7122910&form=6&db=m Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs. therapeutic application,unassigned 1,0 5.3.99.5 Infarction, Middle Cerebral Artery http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7495108&form=6&db=m Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3468120&form=6&db=m Indomethacin in vivo increases the sensitivity to Listeria infection in mice. A possible role for macrophage thromboxane A2 synthesis. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23409199&form=6&db=m Trypanosoma cruzi infection and endothelin-1 cooperatively activate pathogenic inflammatory pathways in cardiomyocytes. unassigned - 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1979954&form=6&db=m Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10848666&form=6&db=m Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. therapeutic application,unassigned 4,0 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11552902&form=6&db=m Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11986343&form=6&db=m Thromboxane synthase immunohistochemistry in inflammatory bowel disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17685873&form=6&db=m Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Inflammatory Bowel Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18457468&form=6&db=m Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11641301&form=6&db=m Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Intracranial Aneurysm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2569686&form=6&db=m Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. therapeutic application,unassigned 3,0 5.3.99.5 Intracranial Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8327988&form=6&db=m Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2960210&form=6&db=m Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Intracranial Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11464470&form=6&db=m [Antithrombotic therapy in cerebral infarction] causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Iron Overload http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26211743&form=6&db=m Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7557557&form=6&db=m Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12235794&form=6&db=m [Strategy for circulatory disturbance] therapeutic application,unassigned 4,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12910992&form=6&db=m [The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction] causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19046748&form=6&db=m Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28108096&form=6&db=m Variants in COX-2, PTGIS, and TBXAS1 Are Associated with Carotid Artery or Intracranial Arterial Stenosis and Neurologic Deterioration in Ischemic Stroke Patients. causal interaction,unassigned 2,0 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29623931&form=6&db=m Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 5.3.99.5 Ischemic Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30417783&form=6&db=m Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities. therapeutic application,unassigned 4,0 5.3.99.5 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1825400&form=6&db=m Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2133429&form=6&db=m Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. causal interaction,therapeutic application,unassigned 3,1,0 5.3.99.5 Kidney Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7981906&form=6&db=m The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300. unassigned - 5.3.99.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1337046&form=6&db=m Manipulation of thromboxane synthesis by novel 26,27-dialkyl analogues of 1 alpha,25-dihydroxyvitamin D3 in human promyelocytic leukemia (HL-60) cells. ongoing research,unassigned 3,0 5.3.99.5 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1742485&form=6&db=m Differentiation-associated expression of prostaglandin H and thromboxane A synthases in monocytoid leukemia cell lines. causal interaction,unassigned 3,0 5.3.99.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1633871&form=6&db=m Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester. ongoing research,unassigned 4,0 5.3.99.5 Leukemia, Erythroblastic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18549804&form=6&db=m Increased cyclooxygenase-2 and thromboxane synthase expression is implicated in diosgenin-induced megakaryocytic differentiation in human erythroleukemia cells. causal interaction,unassigned 2,0 5.3.99.5 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2936143&form=6&db=m Renal effects of cyclooxygenase and thromboxane synthetase inhibitors in dogs with experimental liver disease and in rats with glomerulonephritis. ongoing research,unassigned 4,0 5.3.99.5 Liver Diseases, Alcoholic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9262373&form=6&db=m Alterations in thromboxane synthase and thromboxane A2 receptors in experimental alcoholic liver disease. unassigned - 5.3.99.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1399989&form=6&db=m Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 5.3.99.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900402&form=6&db=m Inhibition of cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3755131&form=6&db=m Effects of thromboxane synthase inhibition on air emboli lung injury in sheep. causal interaction,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3898941&form=6&db=m Effects of OKY-046, a selective thromboxane synthetase inhibitor, on endotoxin-induced lung injury in unanesthetized sheep. causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 5.3.99.5 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15099446&form=6&db=m Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. causal interaction,therapeutic application,unassigned 2,3,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870920&form=6&db=m Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19576211&form=6&db=m Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20647010&form=6&db=m Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB. causal interaction,therapeutic application,unassigned 3,2,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20818420&form=6&db=m 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A(2) and its receptor. causal interaction,unassigned 3,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21388528&form=6&db=m Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24115277&form=6&db=m Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,3 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24480048&form=6&db=m Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24695790&form=6&db=m 18?-Glycyrrhetinic Acid Suppresses Cell Proliferation through Inhibiting Thromboxane Synthase in Non-Small Cell Lung Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,3,1 5.3.99.5 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26518146&form=6&db=m Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. causal interaction,unassigned 3,0 5.3.99.5 Lupus Erythematosus, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2801326&form=6&db=m Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 5.3.99.5 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8743126&form=6&db=m Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. ongoing research,therapeutic application,unassigned 1,4,0 5.3.99.5 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8895147&form=6&db=m Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis. diagnostic usage,therapeutic application,unassigned 3,4,0 5.3.99.5 Lupus Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9561116&form=6&db=m Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis. therapeutic application,unassigned 4,0 5.3.99.5 Lymphoma, Non-Hodgkin http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3100032&form=6&db=m Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 5.3.99.5 Malaria, Cerebral http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31541129&form=6&db=m L-arginine supplementation and thromboxane synthase inhibition increases cerebral blood flow in experimental cerebral malaria. therapeutic application,unassigned 3,0 5.3.99.5 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3361885&form=6&db=m Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma. unassigned - 5.3.99.5 Memory Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34534530&form=6&db=m Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia. ongoing research,unassigned 3,0 5.3.99.5 Mesenteric Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1704141&form=6&db=m The effects of prostacyclin analogue ZK 36374 and thromboxane synthetase inhibitor UK 38485 on mesenteric ischemia in guinea pigs. ongoing research,unassigned 1,0 5.3.99.5 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26211743&form=6&db=m Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 5.3.99.5 Mesothelioma, Malignant http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26211743&form=6&db=m Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model. causal interaction,diagnostic usage,ongoing research,unassigned 2,3,4,0 5.3.99.5 Migraine Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3839492&form=6&db=m Thromboxane synthetase inhibition: potential therapy in migraine. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Mucocutaneous Lymph Node Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1905778&form=6&db=m Implication of thromboxane in the pathogenesis of Kawasaki disease and a suggestion for using novel thromboxane synthetase inhibitors in its treatment. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2020088&form=6&db=m Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2513429&form=6&db=m Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2929400&form=6&db=m The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. diagnostic usage,ongoing research,unassigned 3,2,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3227051&form=6&db=m Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3532743&form=6&db=m Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046). ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3755540&form=6&db=m CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion. diagnostic usage,therapeutic application,unassigned 3,2,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3857643&form=6&db=m Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction. diagnostic usage,therapeutic application,unassigned 3,4,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4040500&form=6&db=m Augmented thromboxane A2 generation and efficacy of its blockade in acute myocardial infarction. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8313547&form=6&db=m Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). ongoing research,therapeutic application,unassigned 1,4,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8459087&form=6&db=m Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. causal interaction,therapeutic application,unassigned 3,3,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11184633&form=6&db=m Role of a genetic variation in the promoter of human thromboxane synthase gene in myocardial infarction. ongoing research,unassigned 2,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12721335&form=6&db=m BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19046748&form=6&db=m Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20931532&form=6&db=m [Association of the Pro1770Leu polymorphism in CYP5A1 gene with myocardial infarction in Uigur population of Xinjiang.] unassigned - 5.3.99.5 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21215134&form=6&db=m [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. diagnostic usage,ongoing research,unassigned 1,1,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3136950&form=6&db=m Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3768069&form=6&db=m Inhibition of thromboxane synthetase by the imidazole derivative 3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic acid as a novel therapeutic approach to experimental myocardial ischemia. therapeutic application,unassigned 4,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4039460&form=6&db=m The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia. ongoing research,unassigned 2,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538740&form=6&db=m Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542777&form=6&db=m Selective thromboxane synthetase inhibitor and ischemic heart disease. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6682567&form=6&db=m Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor. diagnostic usage,ongoing research,therapeutic application,unassigned 2,4,1,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6686001&form=6&db=m Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6891441&form=6&db=m Salutary actions of thromboxane synthetase inhibition during global myocardial ischemia. causal interaction,unassigned 2,0 5.3.99.5 Myocardial Ischemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22419696&form=6&db=m A sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 5.3.99.5 Myocardial Stunning http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2297841&form=6&db=m Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart. causal interaction,therapeutic application,unassigned 2,2,0 5.3.99.5 Neonatal Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3520468&form=6&db=m Effects of the thromboxane synthetase inhibitor, dazmegrel (UK 38,485), on pulmonary gas exchange and hemodynamics in neonatal sepsis. ongoing research,unassigned 1,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3100032&form=6&db=m Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3815323&form=6&db=m Eicosanoids and metastasis: experimental aspects in Lewis lung carcinoma. therapeutic application,unassigned 1,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7051034&form=6&db=m Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575). therapeutic application,unassigned 3,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8510699&form=6&db=m Thromboxane synthase and organ preference for metastases. therapeutic application,unassigned 1,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8525071&form=6&db=m Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10623605&form=6&db=m Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630766&form=6&db=m The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ongoing research,unassigned 4,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17603559&form=6&db=m Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20122998&form=6&db=m The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22037941&form=6&db=m The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. causal interaction,unassigned 3,0 5.3.99.5 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23349788&form=6&db=m Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1399989&form=6&db=m Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2154265&form=6&db=m The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat. causal interaction,therapeutic application,unassigned 3,2,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2314052&form=6&db=m Effects of systemic complement activation and neutrophil-mediated pulmonary injury on the retention and metastasis of circulating cancer cells in mouse lungs. ongoing research,therapeutic application,unassigned 1,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3100032&form=6&db=m Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,2 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6195028&form=6&db=m Role of postaglandins in metastatic dissemination of cancer. Minireview on cancer research. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6195029&form=6&db=m Role of prostaglandins in metastatic dissemination of cancer. Minireview on cancer research. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7051034&form=6&db=m Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575). therapeutic application,unassigned 3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7683632&form=6&db=m Phenotypic properties of cultured tumor cells: integrin alpha IIb beta 3 expression, tumor-cell-induced platelet aggregation, and tumor-cell adhesion to endothelium as important parameters of experimental metastasis. ongoing research,therapeutic application,unassigned 4,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8234474&form=6&db=m The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. therapeutic application,unassigned 4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8525071&form=6&db=m Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8566149&form=6&db=m G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. ongoing research,therapeutic application,unassigned 2,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12154203&form=6&db=m Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14586398&form=6&db=m Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. causal interaction,therapeutic application,unassigned 4,2,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14742249&form=6&db=m Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. causal interaction,diagnostic usage,ongoing research,unassigned 4,2,4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15067173&form=6&db=m Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16250911&form=6&db=m Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16627914&form=6&db=m Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16709411&form=6&db=m Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. causal interaction,diagnostic usage,ongoing research,unassigned 2,1,4,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17603559&form=6&db=m Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17880908&form=6&db=m Activation of extracellular signal-regulated kinase by 12-hydroxyheptadecatrienoic acid in prostate cancer PC3 cells. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18172303&form=6&db=m Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,2,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19107625&form=6&db=m Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases. unassigned - 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20122998&form=6&db=m The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. causal interaction,ongoing research,therapeutic application,unassigned 4,2,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20165694&form=6&db=m Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. causal interaction,therapeutic application,unassigned 4,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20647010&form=6&db=m Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB. causal interaction,therapeutic application,unassigned 3,2,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21040737&form=6&db=m Apigenin inhibits tumor necrosis factor alpha plus high glucose induced-LOX-1 expression in human endothelial cells. ongoing research,therapeutic application,unassigned 4,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21145843&form=6&db=m The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21388528&form=6&db=m Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22037941&form=6&db=m The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. causal interaction,unassigned 3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22493072&form=6&db=m Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23349788&form=6&db=m Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein -1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24115277&form=6&db=m Thromboxane A2 receptor ? promotes tumor growth through an autoregulatory feedback pathway. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,4,3 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24384873&form=6&db=m Thromboxane A2 exerts promoting effects on cell proliferation through mediating cyclooxygenase-2 signal in lung adenocarcinoma cells. ongoing research,therapeutic application,unassigned 4,2,0 5.3.99.5 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24480048&form=6&db=m Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. causal interaction,diagnostic usage,unassigned 2,3,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2450713&form=6&db=m The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse. ongoing research,therapeutic application,unassigned 3,2,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3109872&form=6&db=m The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions. unassigned - 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3317092&form=6&db=m Rabbit nephrotoxic nephritis: effect of a thromboxane synthetase inhibitor on evolution and prostaglandin excretion. ongoing research,unassigned 1,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3480754&form=6&db=m Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit. causal interaction,diagnostic usage,unassigned 1,1,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563970&form=6&db=m Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7982449&form=6&db=m Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats. ongoing research,therapeutic application,unassigned 1,3,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9032136&form=6&db=m Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. therapeutic application,unassigned 1,0 5.3.99.5 Nephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10560941&form=6&db=m Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 5.3.99.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1588545&form=6&db=m Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2402113&form=6&db=m [The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation] causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3214971&form=6&db=m Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Nephrotic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7893785&form=6&db=m The effect of a thromboxane A2 synthase inhibitor on the dyslipoproteinemia of an inbred rat strain with spontaneous age-related nephrotic syndrome. ongoing research,unassigned 3,0 5.3.99.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33346090&form=6&db=m Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. causal interaction,therapeutic application,unassigned 2,1,0 5.3.99.5 Neuroinflammatory Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34534530&form=6&db=m Thromboxane A2 synthase inhibition ameliorates endothelial dysfunction, memory deficits, oxidative stress and neuroinflammation in rat model of streptozotocin diabetes induced dementia. ongoing research,unassigned 3,0 5.3.99.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3326847&form=6&db=m A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 5.3.99.5 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12409963&form=6&db=m Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. unassigned - 5.3.99.5 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11061613&form=6&db=m A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. diagnostic usage,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Pancytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28868793&form=6&db=m Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency. causal interaction,unassigned 4,0 5.3.99.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2148849&form=6&db=m Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,1,1 5.3.99.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6297527&form=6&db=m Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 5.3.99.5 Peripheral Arterial Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15474700&form=6&db=m Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 5.3.99.5 Peripheral Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6681701&form=6&db=m Initial impressions of dazoxiben in the treatment of the ischaemic limb. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6339712&form=6&db=m Gentamicin and indomethacin in the treatment of septic shock: effects on prostacyclin and thromboxane A2 production. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7528364&form=6&db=m Acute renal failure and sepsis: therapeutic approaches. ongoing research,therapeutic application,unassigned 4,4,0 5.3.99.5 Peritonitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9637307&form=6&db=m Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Pituitary Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15067173&form=6&db=m Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,1 5.3.99.5 Pleurisy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2128168&form=6&db=m Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345. diagnostic usage,unassigned 3,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1756996&form=6&db=m Antithromboxane drug in the treatment of preeclampsia. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2589456&form=6&db=m Effects of thromboxane synthetase inhibition on maternal-fetal homeostasis in gravid ewes with ovine pregnancy-induced hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8175982&form=6&db=m Eicosanoid biosynthetic enzymes in placental and decidual tissues from preeclamptic pregnancies: increased expression of thromboxane-A2 synthase gene. causal interaction,therapeutic application,unassigned 3,2,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8378539&form=6&db=m Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy. unassigned - 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8424131&form=6&db=m Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8449429&form=6&db=m Effects of thromboxane synthetase inhibitor (OKY-046) on placental blood flow, placental weight and fetal weight in normotensive and spontaneously hypertensive rats. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8775905&form=6&db=m The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Pre-Eclampsia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22493072&form=6&db=m Reduced methylation of the thromboxane synthase gene is correlated with its increased vascular expression in preeclampsia. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1588545&form=6&db=m Treatment of membranoproliferative glomerulonephritis and nephrotic syndrome in a dog with a thromboxane synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1992126&form=6&db=m Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives. therapeutic application,unassigned 4,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2402113&form=6&db=m [The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation] causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2801326&form=6&db=m Effects of dazmegrel, piroxicam and cyclophosphamide on the NZB/W model of SLE. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3230687&form=6&db=m [Effects of a selective thromboxane A2 synthetase inhibitor, OKY-046, on proteinuria of aminonucleoside nephrotic rats] ongoing research,therapeutic application,unassigned 4,4,0 5.3.99.5 Proteinuria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7563970&form=6&db=m Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 5.3.99.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3287320&form=6&db=m Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel. therapeutic application,unassigned 2,0 5.3.99.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22837860&form=6&db=m Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. causal interaction,unassigned 3,0 5.3.99.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23676973&form=6&db=m Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Pulmonary Arterial Hypertension http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23803333&form=6&db=m Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Pulmonary Edema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3693233&form=6&db=m Alpha-thrombin-induced pulmonary vasoconstriction. causal interaction,therapeutic application,unassigned 1,1,0 5.3.99.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1311763&form=6&db=m 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. therapeutic application,unassigned 1,0 5.3.99.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3686459&form=6&db=m Effect of OKY 046, a thromboxane synthase inhibitor, on lung vascular permeability after pulmonary embolism in sheep. ongoing research,therapeutic application,unassigned 2,4,0 5.3.99.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12639842&form=6&db=m Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Pulmonary Embolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15121765&form=6&db=m Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Pulmonary Eosinophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11698072&form=6&db=m Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 5.3.99.5 Pulmonary Fibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16155090&form=6&db=m Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. causal interaction,ongoing research,therapeutic application,unassigned 2,1,1,0 5.3.99.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6593268&form=6&db=m Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 5.3.99.5 Renal Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15207526&form=6&db=m Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7545331&form=6&db=m Reduction of reperfusion injury in rat skeletal muscle following administration of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 5.3.99.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8005166&form=6&db=m Effects of thromboxane A2 synthetase inhibitor (CV-4151) on reperfused skeletal muscle in rats. ongoing research,unassigned 3,0 5.3.99.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10369085&form=6&db=m The effects of thromboxane synthase inhibition on reperfusion injury and endothelin-1,2 levels in allograft kidney transplantation in rats. causal interaction,ongoing research,unassigned 1,3,0 5.3.99.5 Reperfusion Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15000260&form=6&db=m Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1900683&form=6&db=m Role of arachidonic acid metabolites in oleic acid induced pulmonary injury in a canine model. Effect of ketoconazole (thromboxane synthetase inhibitor). ongoing research,unassigned 4,0 5.3.99.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4039645&form=6&db=m Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Respiratory Distress Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8222677&form=6&db=m A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 5.3.99.5 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6542601&form=6&db=m [Protective effect of a thromboxane synthetase inhibitor, OKY-046, in patients with acute respiratory failure] causal interaction,diagnostic usage,unassigned 3,3,0 5.3.99.5 Respiratory Insufficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8137655&form=6&db=m [The effect of cyclooxygenase and thromboxane synthetase inhibition on oxygen metabolism in canine acute respiratory failure] causal interaction,ongoing research,therapeutic application,unassigned 2,3,3,0 5.3.99.5 Scleroderma, Systemic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12154203&form=6&db=m Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 5.3.99.5 Seizures http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4009745&form=6&db=m The effect of inhibiting brain thromboxane biosynthesis on pentylenetetrazole-induced seizure threshold. ongoing research,unassigned 2,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2673060&form=6&db=m Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2916566&form=6&db=m The protective effect of thromboxane synthetase inhibition on renal function in systemic sepsis. ongoing research,unassigned 2,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3287320&form=6&db=m Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel. therapeutic application,unassigned 2,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3317581&form=6&db=m Effects of a specific thromboxane synthetase inhibitor in equine endotoxaemia. causal interaction,therapeutic application,unassigned 2,4,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6683924&form=6&db=m Thromboxane synthetase inhibitors in septic shock. ongoing research,unassigned 4,0 5.3.99.5 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8044389&form=6&db=m Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2326771&form=6&db=m Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6576388&form=6&db=m Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6585848&form=6&db=m Protection of myocardial function during endotoxin shock by ibuprofen. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6683924&form=6&db=m Thromboxane synthetase inhibitors in septic shock. ongoing research,unassigned 4,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10480288&form=6&db=m Induction of cytosolic phospholipase A2 and prostaglandin H2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes. causal interaction,unassigned 1,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10774620&form=6&db=m Effects of the combined thromboxane receptor antagonist and synthase inhibitor DTTX-30 on intestinal O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. ongoing research,unassigned 3,0 5.3.99.5 Shock, Septic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15278626&form=6&db=m A selective thromboxane synthetase inhibitor, OKY-046, fails to improve blood rheology in endotoxin-shocked rabbits. therapeutic application,unassigned 2,0 5.3.99.5 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15870920&form=6&db=m Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 5.3.99.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6686219&form=6&db=m Roles of thromboxanes in gastrointestinal physiopathology. therapeutic application,unassigned 3,0 5.3.99.5 Spasm http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12224820&form=6&db=m Intracoronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm. causal interaction,therapeutic application,unassigned 2,3,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1867616&form=6&db=m Effects of Furegrelate (Upjohn 63557A) on patency and platelet deposition after canine carotid endarterectomy. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2285016&form=6&db=m Interference of levamisole with cerebral edema. therapeutic application,unassigned 1,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3413813&form=6&db=m Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12235794&form=6&db=m [Strategy for circulatory disturbance] therapeutic application,unassigned 4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19114962&form=6&db=m The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21892396&form=6&db=m Thromboxane A2 synthetase inhibitor plus low dose aspirin : can it be a salvage treatment in acute stroke beyond thrombolytic time window. therapeutic application,unassigned 4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24955863&form=6&db=m N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28478978&form=6&db=m Interactions among Variants in Eicosanoid Genes Increase Risk of Atherothrombotic Stroke in Chinese Populations. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31026093&form=6&db=m Thromboxane A synthase 1 gene expression and promotor haplotypes are associated with risk of large artery-atherosclerosis stroke in Iranian population. diagnostic usage,ongoing research,unassigned 2,4,0 5.3.99.5 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33390963&form=6&db=m Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase. therapeutic application,unassigned 4,0 5.3.99.5 Stroke, Lacunar http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8888028&form=6&db=m [Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction] causal interaction,diagnostic usage,ongoing research,therapeutic application 2,1,4,3 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1891755&form=6&db=m Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2028380&form=6&db=m Effects of subarachnoid hemorrhage and a thromboxane A2 synthetase inhibitor on intracranial prostaglandins. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2218850&form=6&db=m Effect of diltiazem and thromboxane A2 synthetase inhibitor (OKY-046) on vessels following experimental subarachnoid hemorrhage. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3541826&form=6&db=m [Prevention of vasospasm following subarachnoid hemorrhage using a thromboxane A2 synthetase inhibitor (OKY-046)--clinical study among multiple institutions] therapeutic application,unassigned 4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3827476&form=6&db=m [Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046] ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539367&form=6&db=m Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7201009&form=6&db=m Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Subarachnoid Hemorrhage http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9919901&form=6&db=m Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,3 5.3.99.5 Tachycardia, Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2418290&form=6&db=m Thromboxane A2 does not contribute to arrhythmogenesis during evolving canine myocardial infarction. diagnostic usage,therapeutic application,unassigned 1,3,0 5.3.99.5 Tachycardia, Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3227051&form=6&db=m Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=511008&form=6&db=m Platelet-lung in vivo interactions: an artifact of a multi-purpose model? causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2932197&form=6&db=m CGS 12970: a novel, long acting thromboxane synthetase inhibitor. causal interaction,unassigned 1,0 5.3.99.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3016060&form=6&db=m Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. causal interaction,unassigned 4,0 5.3.99.5 Thrombocytopenia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4089809&form=6&db=m Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. therapeutic application,unassigned 3,0 5.3.99.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2996185&form=6&db=m Cerebral platelet thromboembolism and thromboxane synthetase inhibition. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6356465&form=6&db=m Mechanism of action of dipyridamole. therapeutic application,unassigned 2,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=69127&form=6&db=m Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits. ongoing research,therapeutic application,unassigned 1,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1451271&form=6&db=m Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1470226&form=6&db=m Photochemically induced thrombosis of the rat coronary artery and functional evaluation of thrombus formation by occurrence of ventricular arrhythmias. Effects of acetylsalicylic acid and a thromboxane A2 synthetase inhibitor of thrombus formation. causal interaction,ongoing research,unassigned 1,2,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1830517&form=6&db=m Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. causal interaction,ongoing research,therapeutic application,unassigned 1,2,2,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2145320&form=6&db=m Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. therapeutic application,unassigned 2,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2580139&form=6&db=m Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis. diagnostic usage,therapeutic application,unassigned 1,1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2717519&form=6&db=m Pharmacokinetics of furegrelate after oral administration to normal humans. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3134741&form=6&db=m Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis. causal interaction,diagnostic usage,therapeutic application,unassigned 2,3,1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3146820&form=6&db=m Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. ongoing research,therapeutic application,unassigned 4,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3183064&form=6&db=m Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3298621&form=6&db=m Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits. causal interaction,ongoing research,therapeutic application,unassigned 2,3,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3516906&form=6&db=m Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents. diagnostic usage,therapeutic application,unassigned 3,1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3735129&form=6&db=m Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury. causal interaction,unassigned 4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3915630&form=6&db=m The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists. unassigned - 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6270303&form=6&db=m Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. causal interaction,therapeutic application,unassigned 2,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6418881&form=6&db=m Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. causal interaction,ongoing research,unassigned 2,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6435186&form=6&db=m Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo. unassigned - 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6504283&form=6&db=m Microsurgical carotid endarterectomy in rats. ongoing research,unassigned 3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6517902&form=6&db=m Carrageenin-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6681705&form=6&db=m Effect of dazoxiben on arterial graft thrombosis in the baboon. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6812674&form=6&db=m Fibrin, red cell and platelet interactions in an experimental model of thrombosis. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6897751&form=6&db=m Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01). causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7495108&form=6&db=m Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7678680&form=6&db=m Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis. unassigned - 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7778056&form=6&db=m Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. causal interaction,unassigned 1,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8032650&form=6&db=m Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8169831&form=6&db=m A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. causal interaction,therapeutic application,unassigned 1,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8217777&form=6&db=m The effect of platelet inhibitory therapy on graft thromboresistance. therapeutic application,unassigned 2,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8588204&form=6&db=m The combination of thrombin inhibitor and thromboxane synthase inhibitor on experimental thrombosis and bleeding. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9175173&form=6&db=m Percutaneous transluminal angioplasty increases thromboxane A2 production in claudicants. therapeutic application,unassigned 4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9806814&form=6&db=m Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. causal interaction,therapeutic application,unassigned 2,4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10575518&form=6&db=m 8th Seah Cheng Siang Memorial Lecture: new antithrombotic agents. therapeutic application,unassigned 3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10680643&form=6&db=m Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. therapeutic application,unassigned 4,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14742735&form=6&db=m Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. ongoing research,therapeutic application,unassigned 4,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15764681&form=6&db=m Testosterone treatment increases thromboxane function in rat cerebral arteries. causal interaction,therapeutic application,unassigned 1,3,0 5.3.99.5 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31708774&form=6&db=m Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. causal interaction,therapeutic application,unassigned 3,4,0 5.3.99.5 Thrombotic Microangiopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7981906&form=6&db=m The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tü 300. unassigned - 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3927594&form=6&db=m [Deficiencies of the prostaglandin system: III. A partial thromboxane synthetase defect] diagnostic usage,unassigned 2,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6268139&form=6&db=m Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism. causal interaction,unassigned 4,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6297527&form=6&db=m Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7459434&form=6&db=m Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. causal interaction,unassigned 4,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7470394&form=6&db=m Hereditary bleeding disorder due to a primary defect in platelet release reaction. causal interaction,unassigned 4,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9833518&form=6&db=m [Platelet thromboxane synthase deficiency] causal interaction,unassigned 4,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25738781&form=6&db=m Thromboxane synthase deficiency improves insulin action and attenuates adipose tissue fibrosis. causal interaction,therapeutic application,unassigned 4,1,0 5.3.99.5 thromboxane-a synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28868793&form=6&db=m Chronic steroid-response pancytopenia and increased bone density due to thromboxane synthase deficiency. causal interaction,unassigned 4,0 5.3.99.5 Thyroid Cancer, Papillary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15475935&form=6&db=m Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 5.3.99.5 Toxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2220946&form=6&db=m Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor. causal interaction,therapeutic application,unassigned 1,1,0 5.3.99.5 Ureteral Obstruction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3464764&form=6&db=m Effect of thromboxane inhibition on renal blood flow in dogs with complete unilateral ureteral obstruction. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16357168&form=6&db=m Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,1 5.3.99.5 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17603559&form=6&db=m Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 5.3.99.5 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21983220&form=6&db=m Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring. causal interaction,unassigned 3,0 5.3.99.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20510674&form=6&db=m Thromboxane A(2) increases endothelial permeability through upregulation of interleukin-8. causal interaction,unassigned 2,0 5.3.99.5 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22293189&form=6&db=m Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. causal interaction,unassigned 4,0 5.3.99.5 Vascular System Injuries http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30300909&form=6&db=m Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/Reperfusion Injury. causal interaction,unassigned 2,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1891755&form=6&db=m Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. causal interaction,therapeutic application,unassigned 1,4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2569686&form=6&db=m Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. therapeutic application,unassigned 3,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2933930&form=6&db=m Prevention of cerebral vasospasm with OKY-046 an imidazole derivative and a thromboxane synthetase inhibitor. A preliminary co-operative clinical study. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3761754&form=6&db=m Beneficial effect of OKY-046, a selective thromboxane A2 synthetase inhibitor, on experimental cerebral vasospasm. ongoing research,therapeutic application,unassigned 4,4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6380217&form=6&db=m Prostacyclin and thromboxane in cerebral vasospasm II: Effects of thromboxane synthetase inhibitor (OKY-1581) on experimentally-induced cerebral vasospasm. ongoing research,therapeutic application,unassigned 1,1,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538355&form=6&db=m Effect of selective inhibitor of thromboxane A2 synthetase on experimental cerebral vasospasm. therapeutic application,unassigned 4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6539367&form=6&db=m Effect of selective inhibitor of thromboxane A2 synthetase on cerebral vasospasm after early surgery. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7201009&form=6&db=m Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8781596&form=6&db=m Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. causal interaction,therapeutic application,unassigned 4,4,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9335226&form=6&db=m Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm. causal interaction,ongoing research,therapeutic application,unassigned 4,3,1,0 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9919901&form=6&db=m Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,1,1,3 5.3.99.5 Vasospasm, Intracranial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10439434&form=6&db=m Effects of thromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm. ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2335849&form=6&db=m Effects of a thromboxane A2 synthetase inhibitor on ventricular fibrillation threshold during coronary artery occlusion and reperfusion. ongoing research,therapeutic application,unassigned 3,4,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2410739&form=6&db=m Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias. causal interaction,unassigned 2,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3227051&form=6&db=m Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. ongoing research,therapeutic application,unassigned 2,2,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3510761&form=6&db=m Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death. causal interaction,therapeutic application,unassigned 1,2,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6538818&form=6&db=m Comments on "The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs". ongoing research,therapeutic application,unassigned 2,1,0 5.3.99.5 Ventricular Fibrillation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6682723&form=6&db=m The effects of RO-22-4679, a thromboxane synthetase inhibitor, on ventricular fibrillation induced by coronary artery occlusion in conscious dogs. ongoing research,therapeutic application,unassigned 2,2,0